Pds biotechnology corp (PDSB)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Sep'14
Operating expenses:
Research and development expenses

7,041

6,099

5,018

3,377

1,659

830

11,397

18,116

26,923

34,311

30,256

30,068

27,068

24,825

23,312

23,095

20,315

17,839

14,993

0

0

0

General and administrative expenses

9,136

10,981

10,696

8,143

6,158

2,788

6,739

10,213

13,988

17,654

16,525

16,087

15,203

14,686

14,132

12,557

11,033

8,658

6,194

0

0

0

Lease termination costs

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restructuring expenses

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

Impairment of machinery and equipment

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

-

Total operating expenses

20,130

21,034

16,686

11,549

7,845

3,646

18,137

28,330

40,912

51,966

46,782

46,155

42,271

39,512

37,444

35,652

31,348

26,498

21,187

0

0

0

Loss from operations

-20,130

-21,034

-16,686

-11,549

-7,845

-3,646

-18,137

-28,330

-40,912

-51,966

-46,782

-46,155

-42,271

-39,512

-37,444

-35,652

-31,348

-26,498

-21,187

0

0

0

Other income (expense):
Bargain purchase gain

1,604

13,334

11,939

11,939

11,729

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

376

353

294

198

23

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

700

543

385

265

212

154

99

51

9

3

0

0

0

Interest expense

32

33

1

2

3

3

590

1,181

1,705

2,180

2,078

1,861

1,497

1,203

918

756

807

816

663

0

0

0

Warrant remeasurement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,879

1,790

0

0

0

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Income taxes (benefit)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net income (loss)

-17,800

-6,998

-4,640

400

3,718

-3,836

-15,920

-26,490

-39,427

-50,859

-46,471

-45,949

-41,820

-38,820

-37,264

-36,635

-32,780

-28,078

-23,637

0

0

0

Comprehensive income (loss)

-17,800

-6,998

-4,640

400

3,718

-3,836

0

0

0

-

0

-

-41,820

-38,820

-37,264

-36,635

-32,780

-28,078

0

0

0

-

Net loss per share, basic and diluted (in dollars per share)

-

-

-1.10

-

-

-

-0.21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Per share information:
Net income (loss) per share, basic (in dollars per share)

-0.39

-

-

-0.75

1.82

-

-

-0.17

-0.24

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per share, diluted (in dollars per share)

-0.39

-

-

-0.75

1.47

-

-

-0.17

-0.24

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used in computing basic net (loss) income per share (in shares)

10,314

-

-

5,175

3,748

-

-

3,338

3,099

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used in computing diluted net (loss) income per share (in shares)

10,314

-

-

5,175

4,625

-

-

3,338

3,099

-

-

-

-

-

-

-

-

-

-

-

-

-

Cumulative dividend on Series C , C-1 and C-2 convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,356

4,621

0

0

0

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-32,435

-28,259

0

0

0

Loss per share attributable to common stockholders basic and diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-0.44

-0.37

-0.44

-0.42

-0.32

-0.37

-0.33

-0.32

10.42

-7.08

-4.30

-3.05

-2.30

Weighted average common shares outstanding basic and diluted (in shares)

-

-

5,246

-

-

-

3,346

-

-

31,321

30,852

30,403

28,998

28,918

28,896

28,828

28,812

27,286

1,688

1,688

1,688

1,688